https://www.selleckchem.com/pr....oducts/BAY-73-4506.h
The COVID-19 pandemic has affected health-care systems worldwide, including the outpatient spasticity care with botulinum neurotoxin toxin type A (BoNT-A). The aim was to investigate the impact of discontinuation of BoNT-A treatment on patients living with spasticity during the COVID-19 quarantine. A multicentric cross-sectional study. Outpatients setting. Patients with spasticity after stroke and traumatic brain injury treated with BoNT-A. A phone-based survey was conducted from March to May, 2020. Based on the International Classi
Like
Comment
Share
